Last reviewed · How we verify
PAL
PAL is a topical palmitoylethanolamide (PEA) formulation that modulates endocannabinoid signaling to reduce inflammation and pain.
PAL is a topical palmitoylethanolamide (PEA) product that modulates endocannabinoid signaling to reduce inflammation and pain. Used for Neuropathic pain (topical), Inflammatory skin conditions.
At a glance
| Generic name | PAL |
|---|---|
| Also known as | PapMV Adjuvant Long lasting immune response, FB-631 |
| Sponsor | Folia Biotech Inc. |
| Drug class | Topical anti-inflammatory/analgesic |
| Target | PPAR-α; endocannabinoid system |
| Modality | Biologic |
| Therapeutic area | Pain management; Dermatology |
| Phase | FDA-approved |
Mechanism of action
PAL delivers palmitoylethanolamide, an endogenous lipid mediator that activates peroxisome proliferator-activated receptor alpha (PPAR-α) and other receptors involved in anti-inflammatory and analgesic pathways. This mechanism reduces neuroinflammation and peripheral inflammation without direct cannabinoid receptor activation. The topical formulation allows localized delivery to affected tissues.
Approved indications
- Neuropathic pain
- Inflammatory skin conditions
Common side effects
- Local skin irritation
- Pruritus
- Erythema
Key clinical trials
- Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants (NA)
- Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support (NA)
- H. Pylori Eradication With Argon Plasma During Endoscopy (NA)
- Benefits of Physical Activity During the School Day to Reduce Mental Fatigue and Optimize Cognitive and Psychosocial Processes in Secondary School Students (NA)
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal) (NA)
- Effect of Intermittent Fasting and Mediterranean Diet on Body Composition and Nutritional Intake (NA)
- Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) (PHASE3)
- Comparison of the Integrated Posterior-Anterior-Lateral Approach and the Posterior Approach in Robotic Radical Prostatectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAL CI brief — competitive landscape report
- PAL updates RSS · CI watch RSS
- Folia Biotech Inc. portfolio CI